
Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)
CureVac puts lead oncology candidate on back burner and will only move it forward in combination therapies
CureVac is putting its lead cancer therapy on ice — for now.
The trans-atlantic pharma with offices in Boston, MA and Germany put word of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.